- This event has passed.
Presenter(s): Joshua D. Lee MD, MSc
Webinar description: Opioid use disorder is a chronic relapsing disorder, conveying serious risks including disability, incarceration, transmission of blood-borne infections, and death from opioid overdose. There is now nearly a half century of overwhelming evidence that agonist substitution, initially with methadone and more recently with buprenorphine, is both efficacious in clinical trials and effective in the community in promoting and sustaining abstinence and reducing risks associated with opioid use disorder.
This webinar will examine the largest such evaluation to date of XR-NTX opioid treatment compared to a gold standard of care, buprenorphine maintenance.
- Explain the aims and methods of the X:BOT trial, a large US multisite RCT of XR-NTX vs. Bup-Nx beginning on detoxification inpatient units and continuing through 24-weeks of outpatient office-based treatment.
- Compare and contrast XR-NTX vs. BUP-NX effects on relapse-free survival, opioid use rates, and overdose events.
The American Psychiatric Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The American Psychiatric Association designates this enduring material for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.